Sartorius AG. (12/5/19). "Press Release: Sartorius Supervisory Board Extends Appointment of Group CEO Joachim Kreuzburg". Göttingen.

	Organisation	Sartorius AG
	Group	Sartorius (Group)
	Organisation 2	Sartorius (Group)
	Product	laboratory equipment and instruments
	Product 2	bioreactor, disposable
	Person	Kreuzburg, Joachim (Sartorius 200305– CEO)
	Person 2	Kappich, Lothar (Sartorius 201707– Chairman of Supervisory Board joined Board 4/07)

At today’s meeting, the Supervisory Board of Sartorius AG passed the resolution to extend the appointment of the Group CEO, Dr. Joachim Kreuzburg, ahead of schedule by another five-year period to November 10, 2025. "We are very pleased to continue our extraordinarily good cooperation with Joachim Kreuzburg," said Dr. Lothar Kappich, Chairman of the Supervisory Board. "Under his leadership, Sartorius has developed outstandingly. Joachim Kreuzburg is pursuing the right strategy and winning over employees to embrace ambitious goals. By extending his contract, we are ensuring the necessary continuity at the top of the company following the two new appointments to the Executive Board made at the beginning of the year.”

Kreuzburg emphasized, “Sartorius is a great company with an outstanding team and unusually diverse development opportunities. I am very pleased to be able to continue to shape the future of the company.” Kreuzburg has been a member of the Executive Board since November 11, 2002, and the Group’s top-level executive since May 1, 2003.

Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.

Curriculum Vitae of Joachim Kreuzburg https://www.sartorius.com/en/company/about-sartorius-ag/executive-board

Current Photo https://www.sartorius.com/en/company/newsroom/downloads-publications

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2018, Sartorius earned sales revenue of around 1.57 billion euros. Currently, more than 8,900 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Petra Kirchhoff | Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686 | petra.kirchhoff@sartorius.com | www.sartorius.com

Record changed: 2019-12-11